<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889941</url>
  </required_header>
  <id_info>
    <org_study_id>SU-02082009-1758</org_study_id>
    <nct_id>NCT00889941</nct_id>
  </id_info>
  <brief_title>Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK</brief_title>
  <official_title>Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the size of the pupil has an effect on
      quality of vision in patients undergoing LASIK surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To prospectively evaluate the effect of preoperative pupil size on quality of vision
      after wavefront-guided LASIK.

      Methods: Fifty-one patients underwent LASIK for low myopia and completed questionnaires
      regarding specific visual symptoms before and after surgery. Each eye was evaluated
      postoperatively at 1-week, 1-, 3-, 6- and 12-months. Pupils were stratified according to
      size: small (&lt;5.5mm), medium (5.5 to 6.0mm) and large (&gt;6.0mm). Mesopic pupil size and
      preoperative and postoperative variables were evaluated using analysis of variance (ANOVA). A
      regression model was also performed to determine the correlation between mean spherical
      equivalent and cylinder and visual symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>small</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>medium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>large</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LASIK</intervention_name>
    <description>laser-assisted in situ keratomileusis</description>
    <arm_group_label>small</arm_group_label>
    <arm_group_label>medium</arm_group_label>
    <arm_group_label>large</arm_group_label>
    <other_name>laser-assisted in situ keratomileusis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. no more than 6.00 D of spherical myopia

          2. no more than 3.00 D of refractive astigmatism

          3. a stable refraction (less than 0.50D per year of sphere or cylinder)

          4. a corneal diameter of less than 11.0 mm to allow for suction ring fixation

          5. discontinuation of soft contact wear at least 7 days prior to preoperative evaluation

          6. visual acuity correctable to at least 20/20

          7. age older than 21 years

          8. ability to participate in follow-up examinations for 12 months after LASIK surgery

        Exclusion Criteria:

          1. use of rigid gas permeable contact lens

          2. severe dry eye symptoms

          3. severe blepharitis

          4. anterior segment abnormalities (i.e. cataracts, corneal scarring, or
             neovascularization within 1 mm of intended ablation zone)

          5. recurrent corneal erosion

          6. severe basement membrane disease

          7. progressive or unstable myopia or keratoconus

          8. unstable corneal mires on central keratometry

          9. corneal thickness in which LASIK procedure would result in less than 250 microns of
             remaining posterior corneal thickness below the flap postoperatively

         10. baseline standard manifest refraction of more than 0.75 D in sphere power

         11. or a difference of greater than 0.50 D in cylinder power compared with baseline
             standard cycloplegic refraction

         12. a baseline standard cycloplegic refraction differing more than 0.75 in sphere, 0.50 D
             in cylinder

         13. have a different type of astigmatism (i.e. with-the-rule) when the cylinder is greater
             than 0.50D compared to baseline standard cycloplegic refraction

         14. preoperative assessment of ocular topography and/or aberrations indicates that either
             eye is not suitable candidate for LASIK vision correction procedure (i.e. forme fruste
             keratoconus

         15. corneal warpage, or pellucid marginal degeneration)

         16. previous intraocular or corneal surgery

         17. history of herpes zoster or simplex keratitis

         18. patients on systemic corticosteroid or immunosuppressive therapy

         19. immunocompromised subjects or clinically significant atopic disease

         20. connective tissue disease

         21. diabetes

         22. steroid responder

         23. macular pathology

         24. pregnant or lactating patients

         25. patients with sensitivity to planned study concomitant medications

         26. patients participating in another ophthalmic drug or device clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annie Chan</last_name>
    <role>Sub-Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward E. Manche</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Edward Manche, MD</name_title>
    <organization>Stanford University</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

